The Center for Innovation in Point-of-Care Technologies for HIV/AIDS and Emerging Infectious Diseases at Northwestern University (C-THAN)

西北大学艾滋病毒/艾滋病和新发传染病即时护理技术创新中心 (C-THAN)

• 批准号: 10762198
• 负责人: Chad J Achenbach
• 金额: $ 175.42万
• 依托单位: NORTHWESTERN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-11 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10762198
• 关键词: AIDS related cancer; Address; Adoption; Africa; African; Award; Biomedical Engineering; COVID-19 testing; Charge; Clinical; Clinical Research; Collaborations; Communication; Detection; Development; Devices; Diagnostic; Ebola; Emerging Communicable Diseases; Engineering; Evaluation; Funding; Goals; HIV; HIV/AIDS; HIV/HCV; Hepatitis B; Home; Human immunodeficiency virus test; Individual; Industrialization; Infection; International; Laboratories; Lassa Fever; Lateral; Libraries; Maintenance; Mali; Marketing; Modeling; Molecular; Monitor; Monkeypox; Needs Assessment; Nigeria; Output; Physicians; Point of Care Technology; Principal Investigator; Process; Productivity; Publishing; Research; Research Personnel; Resources; Rift Valley Fever; Scientist; Senegal; Site; South Africa; Specimen; Sputum; Structure; Tanzania; Technology; Testing; Textbooks; Training; Translations; Tuberculosis; United Nations; United States National Institutes of Health; Universities; Validation; Viral; Virus; Work; clinical translation; commercialization; comorbidity; design; diagnostic platform; diagnostic technologies; experience; improved; innovation; low and middle-income countries; manufacture; member; multidisciplinary; non-tuberculosis mycobacteria; program dissemination; programs; prototype; skills; synthetic biology; technology development; technology platform; technology research and development; training opportunity; translational study; validation studies; working group

SUMMARY - OVERALL The Center for Innovation in Point-of-Care Technologies for HIV/AIDS and Emerging Infectious Diseases at Northwestern (C-THAN) proposes to remain a member in the Point-of-Care Technologies Research Network (POCTRN) as a Technology Research and Development Center (TRDC). C-THAN will catalyze innovation in diagnostic technologies through a model that enhances complementary strengths to build multidisciplinary partnerships across technology platforms, clinical, regulatory and commercialization domains with a specific focus on HIV/AIDS and emerging infectious diseases in low- and middle-income countries (LMICs). The C-THAN structure will incorporate clinical, and user needs in the development process while providing expertise and resources to address early barriers to technologic development, validation, and commercialization. The scope of work entails: 1) assessment of unmet clinical needs in POC testing for HIV/AIDS, its co-morbidities, and emerging infectious diseases; 2) develop relevant solicitation topics to address unmet clinical needs; 3) award and manage sub-award projects made by C-THAN; 4) collaborate with relevant scientists, physicians, researchers and engineers; 5) develop essential technical, clinical, industrial and regulatory partnerships; 6) conduct clinical studies and/or provide access to specimens for validation testing of prototype devices; and 7) create training opportunities for technical developers and other stakeholders related to the development of POC and home-based devices. The range of technologies will include POC devices for detection of infection and monitoring of HIV/AIDS and its common potentially fatal co- morbidities including tuberculosis (TB), non-tuberculous mycobacterium (NTM), hepatitis B (HBV), hepatitis C (HCV) and HIV-associated malignancies. Furthermore, emerging, and re-emerging infectious diseases will be addressed by applying our strategy of addressing the urgent diagnostic need of POC testing for SARS-CoV-2 and other emerging infections such as mpox virus, Ebola, Lassa Fever, and Rift Valley Fever, among others. The United Nations Program on HIV and AIDS (UNAIDS) has set the ambitious goal of achieving a 95% detection rate for HIV, placing 95% of those individuals on treatment, and achieving 95% viral suppression in those that are treated. The major premise of this renewal proposal is that these goals will not be met without augmenting the current diagnostic platforms for HIV, its co-morbidities, and emerging infectious diseases with POCs that are affordable, rapid, and easy to use in LMICs requiring minimal skill and maintenance. An emphasis will be directed to specific technologic domains by establishing four working groups (WG) in molecular, lateral flow, synthetic biology, and product engineering. We will leverage the dynamic and productive collaborations established by Northwestern in Africa at nine academic centers in Nigeria, Mali, Senegal, Tanzania, and South Africa.

摘要-总体 艾滋病毒/艾滋病和新兴传染病护理点技术创新中心 西北疾病（C-THAN）建议继续成为护理点技术的成员 研究网络（POCTRN）作为技术研究和开发中心（TRDC）。C-THAN将 通过增强互补优势的模式促进诊断技术的创新， 在技术平台、临床、监管和商业化方面建立多学科合作伙伴关系 特别侧重于中低收入国家艾滋病毒/艾滋病和新出现的传染病 中低收入国家。C-THAN结构将在开发过程中纳入临床和用户需求 同时提供专业知识和资源，以解决技术开发、验证和 商业化工作范围包括：1）评估POC检测中未满足的临床需求， 艾滋病毒/艾滋病及其合并症和新发传染病; 2）制定相关征集主题， 解决未满足的临床需求; 3）奖励和管理C-THAN的子奖励项目; 4）与 相关的科学家，医生，研究人员和工程师; 5）开发必要的技术，临床，工业 和监管伙伴关系; 6）进行临床研究和/或提供样本进行验证 测试原型设备;以及7）为技术开发人员和其他 与POC和家庭设备开发相关的利益相关者。技术的范围将 包括检测感染和监测艾滋病毒/艾滋病及其常见潜在致命并发症POC装置， 疾病包括结核病（TB）、非结核分枝杆菌（NTM）、B型肝炎（HBV）、丙型肝炎 (HCV)和艾滋病相关的恶性肿瘤。此外，新出现和重新出现的传染病将是 通过应用我们的战略来解决SARS-CoV-2 POC检测的紧急诊断需求， 以及其他新出现的感染，如天花病毒、埃博拉病毒、拉沙热和裂谷热等。 联合国艾滋病毒和艾滋病规划署（UNAIDS）制定了实现95%的艾滋病毒/艾滋病感染率的宏伟目标。 艾滋病毒的检测率，使95%的人接受治疗，并在2010年实现95%的病毒抑制。 那些被治疗的人。这一更新建议的大前提是，如果不这样做，这些目标将无法实现。 增强目前艾滋病毒、其合并症和新出现的传染病的诊断平台， 在中低收入国家中使用价格实惠、快速且易于使用的POC，只需最少的技能和维护。一个 将通过建立四个工作组（WG），把重点放在具体的技术领域上， 分子、横向流动、合成生物学和产品工程。我们将利用动态， 西北大学在非洲尼日利亚、马里、 塞内加尔、坦桑尼亚和南非。

项目成果

Diagnosing Tuberculosis: What Do New Technologies Allow Us to (Not) Do?

• DOI: 10.1159/000525142
• 发表时间: 2022
• 期刊: Respiration; international review of thoracic diseases

Antiretroviral-induced adverse drug reactions in HIV-infected patients in Mali: a resource-limited setting experience.

马里艾滋病毒感染者抗逆转录病毒引起的药物不良反应：资源有限的环境经验。

• DOI: 10.18203/2319-2003.ijbcp20191565
• 发表时间: 2019
• 期刊: International journal of basic and clinical pharmacology
• 作者: Oumar,AboubacarAlassane;Dakouo,Mamadou;Tchibozo,Anicet;Maiga,Mamoudou;Landouré,Guida;Abdi-Bogoreh,Raysso;Tulkens,PaulM;Dao,Sounkalo;Yombi,JeanCyr
• 通讯作者: Yombi,JeanCyr

An Unstructured Supplementary Service Data System for Daily Tracking of Patient Samples and Diagnostic Results in a Diagnostic Network in Malawi: System Development and Field Trial.

• DOI: 10.2196/26582
• 发表时间: 2021-07-06
• 期刊: Journal of medical Internet research
• 影响因子: 7.4
• 作者: Killian D;Gibson E;Kachule M;Palamountain K;Bangoh JB;Deo S;Jonasson JO
• 通讯作者: Jonasson JO

Performance Comparison of Xpert HIV-1 Viral Load Assay and Roche Taqman and Abbott M2000 RT in Bamako, Mali.

• DOI: pii: 46953
• 发表时间: 2020
• 期刊: Journal of AIDS & clinical research
• 作者: Kone B;Goita D;Dolo O;Traore D;Sogoba D;Somboro A;Sanogo M;Somboro AM;Coulibaly N;Sanogo A;Diarra Z;Traore M;Maiga AI;Baya B;Sarro YDS;Diarra B;Kone A;Diallo D;Dabitao D;Holl JL;Belson M;Dao S;Murphy RL;Diakite M;Diallo S;Doumbia S;Maiga M
• 通讯作者: Maiga M

Performance of Mali's biosafety level 3 laboratory in the external quality assessment in preparedness of laboratory accreditation and support to clinical trials.

• DOI: 10.4103/ijmy.ijmy_5_20
• 发表时间: 2020-01
• 期刊: International journal of mycobacteriology
• 影响因子: 1.2
• 作者: Coulibaly N;Kone B;Sanogo M;G Togo AC;Diarra B;Sarro YS;Cisse AB;Kodio O;Coulibaly G;Kone M;Baya B;Maiga M;Dabitao D;Belson M;Dao S;Diallo S;Diakite M;Babana AH;Doumbia S
• 通讯作者: Doumbia S